Siegfried’s Acquisition of Noramco, Purisys and Extractas

On January 27, 2026, Siegfried, a leading global Contract Development and Manufacturing Organization for the pharmaceutical industry, announced it has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience (“Extractas”). The acquired businesses include Noramco, Purisys and Extractas, three high-quality small molecules drug substances sites. Cravath is representing Siegfried in connection with the transaction.

The Cravath team is led by partners G.J. Ligelis Jr., Daniel J. Cerqueira and Ryan J. Wichtowski and includes foreign associate attorney Florian Schorn and associates Matthew C. Weinstein, Alexander Williams-Pratt and Brennen Lee on M&A matters; partner Lauren Angelilli and associates Jessica Shung and Frederick Schemel on tax matters; partner Eric W. Hilfers and associates Anna Mikaelyan and S. Celine Li on executive compensation and benefits matters; partner David J. Kappos, of counsel Carys J. Webb and associates Yunhao (Leslie) Liu and M. Noa Ma on intellectual property matters; partner Margaret T. Segall and associate Steven Nosco on antitrust matters; partner Matthew Morreale on environmental matters; and of counsels Joyce Law and Brian M. Budnick on real estate matters. Crawford Rundlett also worked on M&A matters and Jesús Saracho worked on antitrust matters.